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Pharmacokinetic-Hemodynamic Studies of Transdermal Nitroglycerin
in Congestive Heart Failure
PAUL W. ARMSTRONG, MD, FACC
Kingston, Ontario, Canada
Ten patients with chronic congestive heart failure were
studied to assess the hemodynamic effects and bioavail-
ability of a transdermal nitroglycerin delivery system.
Nitrate sensitivity was defined by a prior 20 minute in-
fusion of nitroglycerin, 21 Itg/min. Five patients with a
satisfactory hemodynamic response to intravenous ni-
troglycerin received two nitroglycerin patches of 10 cm2
each and five patients who did not achieve a satisfactory
response to intravenous nitroglycerin (that is, ~2S%
reduction in left ventricular filling pressure) received
larger doses of transdermal nitroglycerin.
In the five nitrate-sensitive patients who received 20
cnr' of transdermal nitroglycerin, one study was ter-
minated at 90 minutes, at which point there was no
detectable hemodynamic response or arterial plasma ni-
troglycerin evident. Two patients had a minimal hemo-
dynamic response and a peak plasma concentration of
1ng/mI. Afourth patient had a short-lived hemodynamic
response at 60 and 120 minutes and a plasma nitroglyc-
The search for a long-acting nitrate preparation has led to
the recent introduction of transdermal delivery systems for
clinical use, Although these products have been widely pro-
moted and used, there has been concern about their efficacy
and bioavailability (1). Long-acting nitrates provide sub-
stantial short- and long-term benefits to some patients with
congestive heart failure (2,3). We have previously dem-
onstrated (4,5) a variable response to intravenous nitro-
glycerin in patients with heart failure and have used this
dose-response information to gauge the initial dose of long-
acting nitrate therapy, that is, nitroglycerin ointment. The
ability to conveniently provide sustained delivery of nitro-
glycerin for 24 hours using a single percutaneous dose form
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erin concentration of 1 nglml at 60 minutes. A fifth pa-
tient had a hemodynamic responsepersistingfor 24 hours
and plasma concentrations between 0.6 and 1.1 ng/mI.
The remaining five patients showed little or no hemo-
dynamic response despite doses of transdermal nitro-
glycerin from 40 to 60 enr', The highest plasma concen-
tration achieved in these patients was 2 ng/ml and there
was no relation between dose administered and plasma
concentration achieved.
In 4 of the 10 patients who subsequently received
nitroglycerin ointment, there were a greater decrease in
left- and right-sided filling pressures and greater in-
crease in plasma nitroglycerin concentrations (from 1.6
to 4.8 ng/ml) than those that.occurred with transdermal
nitroglycerin. These data indicate that doses of trans-
dermal nitroglycerin of 20 to 60 cnr' have limited blo-
availability and minimal hemodynamiceffectsin patients
with advanced heart failure.
(J Am Coll Cardiol1987;9:420-5)
is a potentially attractive therapeutic alternative as compared
with the formulations currently available.
Information concerning efficacy of transdermal nitro-
glycerin in congestive heart failure is limited, however, and
there are no data attesting to bioavailability. Accordingly,
we undertook the present study to assess the hemodynamic
effects and bioavailability of a transdermal nitroglycerin
delivery system in 10 patients with chronic heart failure in
whom prior nitrate sensitivity had been assessed with in-
travenous nitroglycerin.
Methods
Study patients. Ten patients with congestive heart fail-
ure formed the study group: there were six men and four
women aged 23 to 71 years. Five patients had coronary
artery disease as the basis for their heart failure, four had
congestive cardiomyopathy and one had rheumatic valvular
disease. All patients were in functional class III or IV and
refractory to conventional therapy including digoxin and
furosemide. Vasodilators were withheld for 48 hours before
0735-1097/87/$3.50
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the study. Diuretics were used to maintain a balanced fluid
intake and output and digoxin was continued throughout.
Three patients (Patients 1, 3 and 6) had received prior nitrate
therapy. All 10 patients had radiographic documentation of
heart failure defined by cardiomegaly and pulmonary venous
congestion but were free of major edema and ascites at the
time of study.
Treatment protocol. After informed consent was ob-
tained, patients were instrumented for hemodynamic mon-
itoring in a standardized fashion. This included placement
of a Swan-Ganz thermodilution catheter in the pulmonary
artery and a Teflon cannula in the radial artery. Right atrial,
pulmonary artery and pulmonary capillary wedge pressures
obtained by balloon occlusion, as well as systemic arterial
pressure, were monitored. Cardiac output was measured by
thermodilution with injection of 10 ml of ice-cold 5% dex-
trose in water into the right atrium. Determinations were
made in duplicate or more often if there was greater than
10% variation in results.
After a control period of30 minutes or more during which
supine hemodynamic measurements were shown to be re-
producible, a 20 minute infusion of 21 JLg/min of nitro-
glycerin was administered into the arm opposite that con-
taining the radial arterial cannula. Hemodynamic
measurements were undertaken and arterial plasma samples
for nitroglycerin were withdrawn, after which intravenous
nitroglycerin was discontinued. A further period of moni-
toring of at least 60 minutes was undertaken to ensure that
a return to control hemodynamic values had occurred. In
five patients there was a satisfactory response to low dose
intravenous nitroglycerin, that is. with 21 JLg/min there was
a 25% or greater reduction in pulmonary artery diastolic
pressure or pulmonary capillary wedge pressure (hereafter
referred to as left ventricular filling pressure). In these five
subjects, two 10 crrr' nitroglycerin patches (Nitro-Dur trans-
dermal infusion system, 2% nitroglycerin in a glycerin-
water vehicle; manufacturer's in vivo release rate of nitro-
glycerin estimated at 0.5 mg/crrr' per 24 h) were applied to
the chest. In the five remaining patients who did not achieve
a 25% reduction in left ventricular filling pressure at 21
JLg/min of intravenous nitroglycerin, larger doses of trans-
dermal nitroglycerin were applied. The first three patients
in this group (Patients 5, 7 and 8) received 40 em", that is.
one 10 and one 30 crrr' patch, and the last two patients
received 60 ern", that is, two 30 crrr' patches.
After the application oftransdermal nitroglycerin. hemo-
dynamic measurements and arterial samples for plasma ni-
troglycerin determination were taken at 112, I, 2, 4, 6, 8,
12, 18 and 24 hours after application of transdermal nitro-
glycerin, and at 30 minute intervals for the first 90 minutes
after patch removal. Cardiac output was measured hourly
for the first 4 hours. We examined the effects of nitroglyc-
erin ointment (Nitrol 2%. Kremers-Urban Co.) in four pa-
tients (Patients 3, 4. 6 and 10) in whom no change in left
ventricular filling pressure was evident after transdermal
nitroglycerin. Nitroglycerin ointment (I inch [2.54 em] =
12.5 mg) was applied to the chest over a 3 X 3 inch
(7.6 x 7.6 ern) area. The nitroglycerin ointment studies
were conducted between 2 and 7 hours after withdrawal of
transdermal nitroglycerin at a time when the plasma arterial
nitroglycerin concentration had returned to zero.
Blood assays and nitroglycerin infusion administra-
tion. Blood samples were immediately centrifuged at 5°C
and the decanted plasma was frozen at - 20°e. Subsequent
analysis was performed using gas-liquid chromatography
with dinitrobenzene as the internal standard according to a
method we have previously described (6). Nitroglycerin
(Nitrostat IV, 0.08 mg/ml, Warner Lambert Co.) was pre-
pared in glass bottles of 5% dextrose solution to achieve a
final concentration of 100 JLg/ml. The nitroglycerin solution
was delivered from 50 ml glass syringes using a Harvard
infusion pump and Teflon connecting tubing which does not
absorb nitroglycerin.
Measurements and analysis of data. Derived hemo-
dynamic variables were calculated as follows:
. . ,cardiac outputCardiac Index (liters/min per rrr') = 2--_
body surface area
and
MAP - RAP
SVR (units) = --.---
cardiac output
where SVR = systemic vascular resistance. MAP = mean
arterial pressure and RAP = right atrial pressure.
The data were analyzed using paired t tests and analysis
of variance where appropriate.
Results
Hemodynamic response to intravenous nitroglycerin
(Fig. 1). The response of left ventricular filling pressure
and right atrial pressure to intravenous nitroglycerin, 21
JLg/min, in the 10 patients and the resulting plasma arterial
nitroglycerin concentration is illustrated in Figure I. Al-
though the overall response in mean left ventricular filling
pressure was a fall from 32 to 23 mm Hg (p < 0.001). it
is noteworthy that Patients 5, 7. 8. 9 and 10 failed to achieve
a reduction of 25% or more from control left ventricular
filling pressure. Despite this, four of these five patients
(Patient 5 excepted) showed a 25% or greater decrease in
right atrial pressure and for all patients there was a mean
reduction from 10 to 7 mm Hg (p < 0.001). Arterial plasma
nitroglycerin concentration in the 10 patients during the 21
JLg/min nitroglycerin infusion varied from 1.9 to 5.4 ng/ml
(X 3.5) and was unrelated to the hemodynamic response.
Response of nitrate-sensitive patients to transdermal
nitroglycerin (Fig. 2). The response of the five patients
who had a reduction of 25% or greater in left ventricular
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Figure 1. Response of 10patients to 20 minutes of
infusion of intravenous nitroglycerin, 21 ~g/min .
GTN = arterial plasma nitroglycerin concentration;
LVFP = left ventricular filling pressure; RAP =
right atrial pressure. Individual patients are plotted.
e = mean data.
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filling pressure with intravenous nitroglycerin, 21 JLglmin,
and were then treated with transdermal nitroglycerin, 20
ern", is shown in Figure 2. The study was terminated in
Patient I for technical reasons at 90 minutes, at which time
there was no hemodynamic improvement or demonstrable
nitroglycerin in arterial plasma. There was minimal hemo-
dynamic response in Patients 2 and 3 although arterial ni-
troglycerin reached approximately I nglml 60 minutes after
Figure 2. Response of five patients to 20 cm2 transdermal nitro-
glycerin. 'OFF' = time after removal of nitroglycerin patch; other
abbreviations as in Figure I.
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application, and similar concentrations were sustained dur-
ing the subsequent 8 hours. Because no hemodynamic re-
sponse was evident at this point, the transdermal nitroglyc-
erin was removed. Although Patient 4 had an initial
hemodynamic effect at the 60 and 120 minute points this
was short-lived and the correspondingarterial nitroglycerin
concentration was I nglml at 60 minutes and was unde-
tectable beyond 90 minutes. Patient 6 exhibited the greatest
hemodynamic effects after transdermal nitroglycerin and
this patient was also the most sensitive to 21 JLg/min of
intravenous nitroglycerin (Fig. I). This patient had persist-
ing hemodynamic effects for 24 hours after application of
transdermal nitroglycerin along with arterial nitroglycerin
concentrations ranging between 0.6 and 1.1 ng/m!. After
removal of transdermal nitroglycerin, hemodynamics re-
turned to control and plasma nitroglycerin became unde-
tectable.
Response of nitrate-insensitive patients to transder-
mal nitroglycerin (Fig, 3). The remaining five patients
studied (Patients 5, 7, 8, 9 and 10) who failed to achieve
a reduction of 25% or more from control left ventricular
filling pressure with intravenous nitroglycerin received higher
doses of transdermal nitroglycerin. Patient 5, who did not
respond to intravenous nitroglycerin , received transdermal
nitroglycerin, 40 crrr', and had a small reduction in pul-
monary capillary wedge and right atrial pressures at 240
minutes which persisted through the 24 hour study period
and had the highest concentration of plasma nitroglycerin
(approximately 2 ng/m!) of any of the 10 patients in the
study. A prompt decline in arterial nitroglycerin concentra-
tion and an increase in left ventricular filling pressure were
seen after removal of transdermal nitroglycerin. Patients 7
and 8, who also received transdermal nitroglycerin, 40 em",
showed little hemodynamic response and their arterial plasma
concentrations reached approximately I ng/m!. Patients 9
and 10, who received the largest dose of transdermal nitro-
glycerin (60 crrr'), showed no change in left ventricular
filling pressure although there was a slight and transient fall
lACC Vol. 9, No.2
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Discussion
Response to intravenous nitroglycerin. These data
confirm that there is a spectrum of hemodynamic response
to intravenous nitroglycerin, 21 1Lg/min, in patients with
heart failure, In some who failed to reach the hemodynamic
end point of a 25% or greater decrease in pulmonary cap-
illary wedge pressure, there was still a decrease in right
atrial pressure suggesting that a venodilator effect had oc-
Figure 4. Response of four patients (Cases 3, 4, 6 and 10) who
received both transdermal nitroglycerin (GTN) (solid lines) and
nitroglycerin ointment(NGO)(dashed lines). Other abbreviations
as in Figure I.
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nitroglycerin ointment (2 inches on two sites). These doses
of nitroglycerin ointment were selected to approximate the
previous doses of transdermal nitroglycerin and measure-
ments were subsequently performed over 240 minutes. A
more potent hemodynamic effect was seen in Patients 3, 4
and 10 with nitroglycerin ointment as evidenced by the fall
in both pulmonary capillary wedge and right atrial pressures,
but this was not seen in Patient 6, In each of the four patients,
plasma nitroglycerin concentration increased more rapidly
and to a higher peak with nitroglycerin ointment than with
transdermal nitroglycerin.
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in right atrial pressure in Patient 9, Plasma arterial nitro-
glycerin ranged between I and 1,5 ng/ml in these two pa-
tients and their studies were terminated at 12 and 8 hours,
respectively, because of lack of response,
Hemodynamics after transdermal nitroglycerin. In
the overall group of 10 patients, the mean control hemo-
dynamic measurements were as follows: heart rate 97 ±
13 beats/min, arterial pressure 86 ± 15 mm Hg, left ven-
tricular filling pressure 28 ± 8 mm Hg, right atrial pressure
10 ± 4 mm Hg, cardiac index 2.3 ± 0,7 liters/min per rrr'
and total peripheral resistance 22 ± 9 units. Except for
Patient I who was studied for 90 minutes, hemodynamic
data were obtained during the first 480 minutes in all pa-
tients, and no statistically significant change was seen in
any of the hemodynamic variables.
Comparison with nitroglycerin ointment (Fig. 4). The
transdermal nitroglycerin data for Patients 3, 4, 6 and 10
are replotted in Figure 4 to provide a basis for comparison
with data obtained in these patients after application of ni-
troglycerin ointment Patients 3 and 4 received 2 inches
(5,08 ern) of nitroglycerin ointment, Patient 6 received I
inch (2,54) and Patient 10 received 4 inches (5.08 ern) of
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Figure 3. Response of three patients (Cases 5. 7 and 8) to 40 cm
transdermal nitroglycerin and of two patients (Cases 9 and 10) to
60 cm transdermal nitroglycerin (GTN). Abbreviations as in Fig-
ure 1.
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curred but was not transmitted to the left side of the heart.
This could relate to differing pressure-volume characteristics
in the two ventricles. Mean plasma arterial nitroglycerin
during intravenous infusion at hemodynamic steady state
was 3.6 ng/ml in keeping with our previous study at this
infusion rate (5). It seems unlikely that prior nitrate therapy
withheld at least 48 hours before the commencement of our
studies influenced the response to nitrates in the current
study because all three patients who had previously received
it had a good response to intravenous nitroglycerin, 21 /-Lg/min.
Response to transdermal nitroglycerin. In two of the
five nitrate-sensitive patients who received transdermal ni-
troglycerin, 20 ern", there was little hemodynamic effect
and undetectable plasma nitroglycerin in one and plasma
nitroglycerin was evident only at 60 minutes in the other.
In the remaining three patients in this group, sustained plasma
nitroglycerin concentrations of between 0.8 and 1.2 ng/ml
were achieved and were associated with modest hemody-
namic effects. In the five patients who received 40 to 60
crrr' transdermal nitroglycerin there were measurable con-
centrations of nitroglycerin for the duration of patch appli-
cation. However, the plasma nitroglycerin concentrations
were similar to those of the three patients previously dis-
cussed and there was no clear relation between the dose
administered and the plasma concentration achieved. No
hemodynamic effects were evident in these patients. In pre-
vious studies (4) of intravenous nitroglycerin in heart failure,
we suggested a therapeutic range for arterial plasma con-
centration of 1.2 to II ng/ml and identified a subset of
patients who proved hemodynamically refractory to high
doses of intravenous nitroglycerin. Despite achieving con-
centrations in this range after intravenous nitroglycerin, five
of the current study patients failed to achieve the hemo-
dynamic target and were considered to be nitrate resistant.
Plasma concentrations after transdermal nitroglycerin in the
current study were at or below the lower portion of this
concentration range in 8 of our 10 patients. The three pa-
tients who had received prior nitrate therapy were all nitrate
sensitive, indicating that this factor did not affect our results.
Transdermal nitroglycerin versus nitroglycerin oint-
ment. By contrast, when nitroglycerin ointment was ap-
plied to the four patients who were unresponsive to trans-
dermal nitroglycerin, there were more potent hemodynamic
effects in three, and higher plasma concentrations achieved
in all four patients. These data attest to the fact that trans-
cutaneous absorption of nitroglycerin was unimpaired in
these patients. The reasons for the differing bioavailability
between nitroglycerin ointment and transdermal nitroglyc-
erin probably relate to the larger surface area over which
ointment is applied as well as the differing release rates of
the nitroglycerin-containing vehicles in the two prepara-
tions.
In our previous studies (2) of nitroglycerin ointment in
congestive heart failure we showed that doses of 3/4 to 2
inches (that is, 10 to 25 mg) produce hemodynamic benefit
and plasma concentrations in the region of 3 ng/ml. Unlike
the current study, higher doses (4 inches or 50 mg) of
nitroglycerin ointment over a larger surface area were as-
sociated with higher plasma concentrations, demonstrating
a relation between dose applied and plasma concentration
achieved (2). Only I of the 10 patients receiving transdermal
nitroglycerin in the present study achieved a plasma con-
centration comparable with that of low dose nitroglycerin
ointment and it seems therefore unlikely that transdermal
nitroglycerin in the doses used in this study will be of sub-
stantial benefit to most patients with refractory congestive
heart failure. The response of Patient 6, however, highlights
the wide variation in individual response to a uniform dose
of nitroglycerin. This patient had a dramatic decrease in left
ventricular filling pressure with 21 JLg/min of intravenous
nitroglycerin and achieved a plasma concentration of ap-
proximately 3.5 ng/ml; he also had the most marked de-
crease in left ventricular filling pressure with the lowest
dose of transdermal nitroglycerin, during which time a plasma
concentration of 0.5 to I ng/ml was reached and sustained
until removal of the patch.
Comparison with previous studies. The lack of a clear
relation between dose of transdermal nitroglycerin and plasma
concentration in our study contrasts with the data of Muller
et al. (7), who studied six healthy volunteers with trans-
dermal nitroglycerin patches (NTG-TTS, Ciba/Geigy, es-
timated in vitro nitroglycerin release rate 40 /-Lg/h per crrr')
of 10, 20 and 40 ern". At the two lower doses, the highest
nitroglycerin concentration in venous plasma in their study
was 0.3 ng/ml, a value which is at the lower limit of de-
tection by our measurement technique. The concentrations
of 0.5 to 0.7 ng/rnl achieved with 40 crrr' of transdermal
nitroglycerin are in agreement with our findings at that dose
allowing for arterial venous differences (6). Direct com-
parison of their data with our own is complicated by several
factors: I) differing patient populations, that is, normal vol-
unteers versus patients with severe heart failure, 2) differing
circulatory sampling sites, that is, venous versus arterial
sites, and 3) differing in vivo flux rates in the two trans-
dermal systems, that is, 0.96 rug/em? per 24 hours in the
study of Muller et al. versus 0.5 mg/crrr' per 24 hours in
the present study.
Sharpe and Coxon (8) studied eight patients with heart
failure using a transdermal nitroglycerin system identical to
that employed by Muller et al. Using a 10 cnr' patch they
noted a reduction in pulmonary capillary wedge pressure
from 29 to 17 mm Hg that was maintained for 24 hours.
Similar changes Were evident with a 20 crrr' patch in the
same patients. When they compared the hemodynamic ef-
fects of a 10 cnr' nitroglycerin patch with 20 mg oral iso-
sorbide dinitrate and I inch of nitroglycerin ointment (skin
site and area unspecified) they found similar hemodynamic
results. However, this comparison was conducted at a single
JACC Vol. 9, NO.2
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point in time, that is, 4 hours after transdermal nitroglycerin
and 60 minutes after both oral isosorbide and nitroglycerin
ointment. Because the peak hemodynamic effects after both
isosorbide and nitroglycerin ointment often occur later than
60 minutes, the hemodynamic responses to the different
nitrate preparations may have diverged over time. Their
study does demonstrate, however, that a low dose of trans-
dermal nitroglycerin can produce hemodynamic benefit in
some patients with heart failure.
Olivari et al. (9) studied nine patients with heart failure
using the identical transdermal nitroglycerin system used in
the current study. They found significant reductions in pul-
monary capillary wedge pressure and right atrial pressure
that persisted for at least 6 hours after 30 or 40 em? patches
and partially waned by 24 hours. Rajfer et al. (10) also
demonstrated hemodynamic benefit with transdermal nitro-
glycerin in nine patients (the average dose was 51 ± 6 crrr'
and the estimated nitroglycerin delivery was 0.625 mg/crrr'
per 24 h) and selected the dose based on the prior response
to intravenous nitroglycerin. Jordan et al. (II) recently stud-
ied eight patients with heart failure using 120 ern? (or 60
mg/24 h) transdermal nitroglycerin and found modest hemo-
dynamic effects that waned by 18 hours; these workers also
noted a much wider variability in a hemodynamic response
to transdermal nitroglycerin at lower doses. They also ob-
served that the most prominent effect in a single patient was
seen after a 10 cnr' dose consistent with the wide variability
in the response to nitrates in patients with heart failure,
evident in both the present study and our previous work (4).
Basis for the differences between the current study
and previous studies of transdermal nitroglycerin in heart
failure. The reason for the differences between our study
and earlier studies is unclear. One factor to consider in the
interpretation of hemodynamic responses after acute therapy
is that of spontaneously favorable changes during cardiac
catheterization mimicking those of a vasodilator response,
as has recently been emphasized by Packer et al. (12). These
may have been operative in previously reported studies and
in what beneficial effects we observed. Another factor is
that of differences in small patient populations in as het-
erogeneous a disease as heart failure: our study of 10 patients
is the largest of the four reported heart failure studies (8-11).
Differences in etiology, duration and extent of heart failure
can account for substantial variation in interpatient re-
sponses and nitrate sensitivity; for example, the baseline
hemodynamic abnormalities in the patients of Jordan et al.
(II) indicated moderately severe heart failure with average
pulmonary capillary wedge pressure of 21 mm Hg and av-
erage right atrial pressure of 7 mm Hg in contrast to the
more advanced hemodynamic abnormalities in the current
study. Finally, different nitrate doses from a variety of trans-
dermal preparations with differing flux rates were employed.
Although Olivari et al. (9) found hemodynamic deteri-
oration after removal of transdermal nitroglycerin and sug-
gested that it was mediated by a rebound phenomenon sec-
ondary to unopposed vasoconstriction, similar findings were
not observed in two subsequent studies (8,10) nor in the
three patients in our study who were followed up for 24
hours, after which transdermal nitroglycerin was removed.
Conclusions. The current study emphasizes that there
is a spectrum of response to intravenous nitroglycerin in
congestive heart failure and that this is useful in identifying
nitrate-sensitive patients. The failure of most patients in the
current study to respond to transdermal nitroglycerin was
related to nitrate resistance in some, and limited bioavail-
ability of nitroglycerin in others. Our data suggest that trans-
dermal nitroglycerin in the doses employed herein has a
limited role in patients with advanced heart failure and
produces only modest hemodynamic effects in those indi-
viduals who are most nitrate sensitive.
Transdermal nitroglycerin (Nitro-dun was kindly supplied by Alyn Golub.
MD. Key Pharmaceuticals. Inc. It is a pleasure to acknowledge the capable
assistance of the nurses in the coronary care unit of the Kingston General
Hospital, the technical assistance of Susan Kobus and Jim McKinven. the
secretarial assistance of Maureen McClenaghan and Jeanine MacRow and
the constructive critique of Joyce A. Moffat. PhD.
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